STELEX ANNOUNCES SOX PRACTICE FOR LIFE SCIENCE COMPANIES
Approach includes regulatory advice, training and hands-on implementation assistance
Bensalem PA, February 17, 2005— Stelex, a firm providing enterprise wide compliance solutions to the regulated industries, today announced a Sarbanes-Oxley Compliance practice for the Life Science industries.
Stelex has developed a methodology to meet the unique SOX compliance challenges that Life Science companies face. This methodology leverages the existing quality systems companies have developed to comply with FDA regulations to achieve SOX compliance. From planning to operations, the methodology is based on standards set forth by the SEC and IT Governance Board.
“Our Sarbanes-Oxley practice is focused on our Life Science clients and enhances our existing service offerings,” said Michael Khavinson, President of Stelex. “We will continue to help our clients succeed by partnering with them and providing value-based business solutions.”
As part of this offering, Stelex will also provide comprehensive training in SOX compliance and its impact on the Life Sciences industry, through its IACET accredited Stelex University.
About Stelex
Stelex is a consulting firm providing enterprise-wide compliance solutions to regulated industries in the Pharmaceutical, Medical Device, Diagnostic and Biotechnology sectors for over 20 years. The firm delivers a comprehensive suite of Validation, Technology, Regulatory and Business solutions.
Stelex is a subsidiary of
Vital Signs, Inc. (NASDAQ: VITL). Vital Signs provides products and services to the hospital market and FDA regulated industries. The Company was recognized in the October 2003 issue of Forbes Magazine as one of “The 200 Best Small Companies.” Vital Signs is ISO 9001 certified and has CE Mark approval for its products.
All statements in this press release other than historical statements constitute Forward Looking Statements under the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements as a result of a variety of factors, including but not limited to the changes in regulatory requirements in the United States and elsewhere, timing and effectiveness of changes to marketing and sales plans, programs and strategies; market conditions; customer response; technological change; and competition and other factors referred to by Vital Signs in its Annual Report on Form 10-K for the year ended September 30, 2004 and other reports filed with the Securities and Exchange Commission.